| Schedule of Segment Information |
The following represents selected
financial information for our segments for the three and six months ended April 30, 2021 and 2020 and as of April 30, 2021 and October
31, 2020:
| |
|
For the Three Months Ended
April 30, |
|
|
For the Six Months Ended
April 30, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Net Income/(Loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,445,758 |
) |
|
$ |
(495,030 |
) |
|
$ |
(2,406,494 |
) |
|
$ |
(1,125,363 |
) |
| Cancer Vaccines |
|
|
(662,367 |
) |
|
|
(170,271 |
) |
|
|
(1,568,703 |
) |
|
|
(365,867 |
) |
| Anti-Viral Therapeutics |
|
|
(309,755 |
) |
|
|
(309,504 |
) |
|
|
(790,561 |
) |
|
|
(309,504 |
) |
| Cancer Diagnostics |
|
|
(13,409 |
) |
|
|
(1,679,027 |
) |
|
|
(22,371 |
) |
|
|
(3,469,673 |
) |
| Patent Licensing |
|
|
(5,600 |
) |
|
|
(4,158 |
) |
|
|
118,863 |
|
|
|
(4,158 |
)) |
| Total |
|
$ |
(2,436,889) |
|
|
$ |
(2,657,990 |
) |
|
$ |
(4,669,266 |
) |
|
$ |
(5,274,565 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,437,282 |
|
|
$ |
2,670,137 |
|
|
$ |
5,182,913 |
|
|
$ |
5,300,006 |
|
| Less non-cash share-based compensation |
|
|
(1,051,272 |
) |
|
|
(1,110,086 |
)) |
|
|
(2,037,371 |
) |
|
|
(2,131,420 |
) |
Operating costs and expenses
excluding non-cash share-based
compensation |
|
$ |
1,386,010 |
|
|
$ |
1,560,051 |
|
|
$ |
3,145,542 |
|
|
$ |
3,168,586 |
|
Operating costs and expenses excluding
non-cash share based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
934,714 |
|
|
$ |
223,822 |
|
|
$ |
1,492,394 |
|
|
$ |
570,163 |
|
| Cancer Vaccines |
|
|
298,537 |
|
|
|
67,059 |
|
|
|
836,525 |
|
|
|
165,329 |
|
| Anti-Viral Therapeutics |
|
|
138,175 |
|
|
|
221,018 |
|
|
|
408,431 |
|
|
|
221,018 |
|
| Cancer Diagnostics |
|
|
10,291 |
|
|
|
1,044,889 |
|
|
|
16,723 |
|
|
|
2,208,813 |
|
| Patent Licensing |
|
|
4,293 |
|
|
|
3,263 |
|
|
|
391,469 |
|
|
|
3,263 |
|
| Total |
|
$ |
1,386,010 |
|
|
$ |
1,560,051 |
|
|
|
3,145,542 |
|
|
$ |
3,168,586 |
|
| |
|
April 30,
2021 |
|
|
October 31,
2020 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
25,906,018 |
|
|
$ |
2,988,124 |
|
| Cancer Vaccines |
|
|
8,265,734 |
|
|
|
946,923 |
|
| Anti-Viral Therapeutics |
|
|
3,825,876 |
|
|
|
2,464,361 |
|
| Cancer Diagnostics |
|
|
332,450 |
|
|
|
2,869,529 |
|
| Patent Licensing |
|
|
167,444 |
|
|
|
184,027 |
|
| Total |
|
$ |
38,497,522 |
|
|
$ |
9,452,964 |
|
|